Insider entity Symbiosis II trims Clene (CLNN) stake with share sale

Rhea-AI Filing Summary

Clene Inc. insider activity: A Form 4 shows that on February 3, 2026, 5,559 shares of Clene Inc. common stock were sold at $4.10 per share. The shares are held indirectly through Symbiosis II, LLC, an entity associated with 10% owner Ugwumba Chidozie.

After this transaction, 550,000 Clene shares remain beneficially owned indirectly via Symbiosis II, LLC. The filing is for one reporting person and does not involve any derivative securities.

Insider Trade Summary

Net Seller: 5,559 shares ($22,792)

Net Sell 1 txn

Insider Ugwumba Chidozie

Role 10% Owner

Sold 5,559 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,559	$4.10	$23K

Holdings After Transaction: Common Stock — 550,000 shares (Indirect, By Symbiosis II, LLC)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE AR 72712

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		S		5,559	D	$4.1	550,000	I	By Symbiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chidozie Ugwumba	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Clene Inc. (CLNN) report in this Form 4?

Clene Inc. reported a Form 4 showing the sale of 5,559 shares of common stock at $4.10 per share. The shares were held indirectly through Symbiosis II, LLC, an entity associated with 10% owner Ugwumba Chidozie.

Who is the reporting person in the Clene Inc. (CLNN) Form 4 filing?

The reporting person is Ugwumba Chidozie, identified as a 10% owner of Clene Inc. The reported shares are held indirectly through Symbiosis II, LLC, as indicated by the nature of ownership field in the filing.

How many Clene Inc. (CLNN) shares does Symbiosis II, LLC hold after the sale?

Following the reported sale, 550,000 shares of Clene Inc. common stock are shown as beneficially owned. These shares are held indirectly through Symbiosis II, LLC, according to the Form 4’s post-transaction holdings column.

What was the sale price in the Clene Inc. (CLNN) insider transaction?

The Form 4 shows that 5,559 Clene common shares were sold at a price of $4.10 per share. This transaction was coded as an “S” transaction, indicating an open-market or private sale of non-derivative securities.

Is the Clene Inc. (CLNN) Form 4 transaction direct or indirect ownership?

The transaction involves indirect ownership. The Form 4 lists the ownership form as Indirect (I), with the nature of ownership described as “By Symbiosis II, LLC”, rather than shares held directly by the individual.

Does this Clene Inc. (CLNN) Form 4 include any derivative securities?

No, the filing’s Table I shows only a transaction in common stock, a non-derivative security. Table II for derivative securities is present but contains no listed derivative transactions or holdings in this particular Form 4.